Výsledky vyhledávání - "Jenny I. O. Craig"

Akademický článek

Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol

Autor: Niccolò Bolli, Nicla Manes, Thomas McKerrell, Jianxiang Chi, Naomi Park, Gunes Gundem, Michael A. Quail, Vijitha Sathiaseelan, Bram Herman, Charles Crawley, Jenny I. O. Craig, Natalie Conte, Carolyn Grove, Elli Papaemmanuil, Peter J. Campbell, Ignacio Varela, Paul Costeas, George S. Vassiliou

Publikováno v: Haematologica, Vol 100, Iss 2 (2015)

Prognostic stratification is critical for making therapeutic decisions and maximizing survival of patients with acute myeloid leukemia. Advances in the genomics of acute myeloid leukemia have identified several recurrent gene mutations whose prognost

Externí odkaz: https://doaj.org/article/9f037c30503d4893b67eec899001d514

Zobrazit plný text záznamu

High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study

Autor: R. C. F. Leonard, A Hawkins, Robert C. F. Leonard, Hani Gabra, Alistair Parker, L Matheson, William M. Miller, Wilma Jack, Jean A. Mackay, Udi Chetty, Michael Dixon, Jenny I. O. Craig, Thomas J. Anderson, Ian Kunkler, Lisa Lee, David Cameron, Elizabeth Anderson

Publikováno v: British Journal of Cancer. 74:2013-2017

Current treatments for metastatic breast cancer are not associated with significant survival benefits despite response rates of over 50%. High-dose therapy with autologous bone marrow transplantation (ABMT) has been investigated, particularly in Nort

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d00f141b6dc43ff8da50710f0fcdad67
https://doi.org/10.1038/bjc.1996.669

Zobrazit plný text záznamu

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

Autor: Jenny I. O. Craig, Ja Liu Yin, Donald Milligan, Alan Kenneth Burnett, P Cahalin, Jonathan Kell, Ann Hunter, Nigel H. Russell, Robert Kerrin Hills, Keith Wheatley, Deborah J. Bowen, Mary Frances McMullin

Publikováno v: Leukemia

Background Most patients with acute myeloid leukaemia are older, with many unsuitable for conventional chemotherapy. Low dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83cf53bd7a2011d1413b3bf50a6a92c
https://pubmed.ncbi.nlm.nih.gov/21475252

Zobrazit plný text záznamu

The Response of Peripheral Blood Stem Cells to Standard Chemotherapy for Lymphoma

Autor: Susan M. Smith, R. S. Anthony, A. C. Parker, Jenny I. O. Craig

Publikováno v: Leukemia & Lymphoma. 6:363-368

Peripheral blood stem cells (PBSC) represent an alternative to bone marrow for autologous transplantation. These progenitors are found in the blood in greatly increased numbers after chemotherapy for acute leukaemia and after high dose cyclophosphami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e509f73bbb25c18815d2944c0d368a2
https://doi.org/10.3109/10428199209053568

Zobrazit plný text záznamu

Circulating progenitor cells in myelofibrosis: the effect of recombinant α2b interferon in vivo and in vitro

Autor: R. S. Anthony, Jenny I. O. Craig, A. C. Parker

Publikováno v: British Journal of Haematology. 78:155-160

Summary We have studied circulating progenitor cells in patients with myelofibrosis, the effects of recombinant α2b interferon (IFN) treatment on these cells in vivo and in vitro and the patients’clinical response to IFN treatment. A 75-fold incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92c1feda9688e34e29fcd2b10444c94
https://doi.org/10.1111/j.1365-2141.1991.tb04410.x

Zobrazit plný text záznamu

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Autor: Donald Milligan, Timothy Littlewood, Alan K. Burnett, Jenny I. O. Craig, Keith Wheatley

Publikováno v: Blood. 107(12)

The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia (relapsed, resistant/refractory, or adverse genetic disease) is uncertain. The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45db4f6f7a23bc3367f89ca75abe30c
https://pubmed.ncbi.nlm.nih.gov/17114571

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání